Ventripoint Diagnostics Ltd.

As of December 31, 2025, Ventripoint Diagnostics Ltd. carries a market capitalization of 23.69M, placing it among publicly traded companies globally. Its enterprise value stands at 26.25M, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.

As of December 31, 2025, Ventripoint Diagnostics Ltd. has 169.22M shares outstanding.

These figures are as of December 31, 2025. The price-to-sales ratio is 128.93, and the price-to-book ratio stands at -5.75.

These figures are as of December 31, 2025. The EV/Sales ratio of 145.87 reflects the premium investors pay for the company's revenue stream, a useful check when earnings are depressed or negative. These enterprise value multiples are built on an enterprise value of 26.25M versus a market cap of 23.69M, with the gap driven by net debt and cash on the balance sheet.

As of December 31, 2025, Ventripoint Diagnostics Ltd. maintains a current ratio of 0.08, meaning it holds 0.1x the short-term assets needed to cover near-term liabilities. The debt-to-equity ratio is -63.44, indicating conservative leverage, while an interest coverage ratio of -6.35 demonstrates limited ability to service its debt obligations.

These figures cover the twelve months ended December 31, 2025. Return on assets (ROA) is negative at -566.36, reflecting losses generated across the asset base.

As of the close on October 22, 2026, Ventripoint Diagnostics Ltd.'s stock has declined approximately 10.00% over the past 52 weeks. The 50-day moving average sits at 0.10, while the 200-day moving average is 0.11.

Over the twelve months ended December 31, 2025, Ventripoint Diagnostics Ltd. generated 179,928.00 in revenue and converted that into -3.20M in net income, yielding earnings per share of -0.02. EBITDA reached -3.34M, while operating income came in at -3.40M.

As of December 31, 2025, Ventripoint Diagnostics Ltd. holds 55,389.00 in cash and equivalents against 2.61M in total debt, resulting in a net debt position of 2.40M. Total book value stands at -4.12M, with working capital of -4.12M providing operational flexibility.

Ventripoint Diagnostics Ltd. produced -1.55M in operating cash flow over the twelve months ended December 31, 2025.

These figures cover the twelve months ended December 31, 2025. The operating margin of -1,889.37 and net profit margin of -1,778.62 provide insight into operational efficiency.

Over the twelve months ended December 31, 2025, Ventripoint Diagnostics Ltd. paid dividends of - - per share. The dividend payout ratio of - - indicates the proportion of earnings distributed to shareholders, a key gauge of how sustainable the dividend is and how much room remains for future dividend growth. Free cash flow yield is negative at -6.70: the business is consuming cash rather than generating it, so any dividend is not covered by free cash flow. Total shareholder yield is negative at -6.47, meaning Ventripoint Diagnostics Ltd. raised more capital through share issuance and new debt than it returned via dividends and buybacks.

Ventripoint Diagnostics Ltd.'s most recent stock split took place on December 7, 2015 with a 10:1 split ratio.

As of December 31, 2025, Ventripoint Diagnostics Ltd. has an Altman Z-Score of -213.49, below the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.